Clinical Trials Sponsored by PDC Biotech GmbH

Total 87 results

PDC Biotech GmbH

Completed

Dose-Finding Study of PDC31 in Patients With Primary Dysmenorrhea

Dysmenorrhea

Austria, Germany
Hookipa Biotech GmbH

Recruiting

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

HPV-Related Squamous Cell Carcinoma

United States, Spain, Netherlands
F2G Biotech GmbH

Completed

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment

Renal Impairment

United States
APrevent Biotech GmbH

Completed

APrevent Vocal Implant System (VOIS) for Adjustable Treatment of Unilateral Vocal Fold Paralysis (UVFP)

Paralysis, Unilateral, Vocal Cord

Austria
APrevent Biotech GmbH

Recruiting

APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study

Paralysis, Unilateral, Vocal Cord

Austria, United States, Germany
Lindis Biotech GmbH

Recruiting

Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

Urinary Bladder Neoplasms

Germany
Hookipa Biotech GmbH

Completed

A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients

Kidney Transplantation | Cytomegalovirus (CMV) Infection

United States, Denmark, Norway, United Kingdom, Germany, France
F2G Biotech GmbH

Completed

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment

Hepatic Impairment

United States
EURRUS Biotech GmbH

Completed

Study to Assess Pharmacokinetics, Safety, and Tolerability of XC-8

Asthma

Austria, Germany
Hookipa Biotech GmbH

Recruiting

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Metastatic

United States
Hookipa Biotech GmbH

Terminated

A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer

United States
F2G Biotech GmbH
Covance

Completed

A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim

Healthy

United Kingdom
F2G Biotech GmbH
Covance

Completed

Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects

Invasive Aspergillosis

United Kingdom
BioNTech Diagnostics GmbH

Completed

Re-Examination of Tumor Material and Re-Evaluation of Patient Data From Patients Treated With Neo-adjuvant Therapy

Breast Cancer
BioNTech Diagnostics GmbH

Completed

Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit "MammaTyperTM"

Invasive Breast Cancer
Greenovation Biotech GmbH
FGK Clinical Research GmbH

Completed

Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A in Patients With Fabry Disease

Fabry Disease

Germany
BioNTech RNA Pharmaceuticals GmbH

Completed

RBL001/RBL002 Phase I Clinical Trial (MERIT)

Melanoma

Austria, Germany
BioNTech RNA Pharmaceuticals GmbH

Completed

IVAC MUTANOME Phase I Clinical Trial

Melanoma

Austria, Germany
PHARMENTERPRISES LLC
EURRUS Biotech GmbH

Completed

XC8 in the Treatment of Patients With Bronchial Asthma

Bronchial Asthma

Russian Federation
F2G Biotech GmbH
Celerion Ltd

Completed

Study of Potential for Interaction of Fluconazole With F901318

Invasive Aspergillosis

United Kingdom
NKGen Biotech, Inc.
Affimed GmbH

Terminated

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Squamous Cell Carcinoma of Head and Neck | Advanced Solid Tumor | Metastatic Tumor | Refractory Tumor

United States
F2G Biotech GmbH
SimbecRresearch Ltd.

Completed

Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects (ORALMAD)

Invasive Aspergillosis

United Kingdom
F2G Biotech GmbH
Quotient Clinical

Withdrawn

Radiolabelled IV and Oral Metabolism Study of F901318 (ADME)

Invasive Aspergillosis

United Kingdom
F2G Biotech GmbH
Quotient Clinical

Withdrawn

Pharmacokinetics of IV Formulation

Invasive Aspergillosis
F2G Biotech GmbH
Quotient Clinical

Completed

Evaluation of Immediate Release Tablet

Invasive Aspergillosis

United Kingdom
F2G Biotech GmbH
Simbec Research

Completed

F901318 Single Ascending Dose Study in Healthy Male Volunteers

Invasive Aspergillosis

United Kingdom
Facet Biotech
PDL BioPharma, Inc.

Terminated

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

France, Belgium, United States, Israel, Australia, Germany, Netherlands, Austria, Canada, Czech Republic, Ukraine, Norway, Hungary, Slovakia
Facet Biotech
PDL BioPharma, Inc.

Terminated

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

Ulcerative Colitis

Belgium, France, United States, Italy, Canada, Czech Republic, Norway, Israel, Austria, Croatia, Australia, Hungary, Ukraine, Netherlands, Germany
Facet Biotech
PDL BioPharma, Inc.

Withdrawn

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Intravenous Steroid-Refractory Ulcerative Colitis
Facet Biotech
PDL BioPharma, Inc.

Completed

Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis

Severe Ulcerative Colitis

United States
Facet Biotech
PDL BioPharma, Inc.

Completed

Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease

Crohn's Disease

United States
PDL BioPharma, Inc.

Completed

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States, Canada
PDL BioPharma, Inc.

Terminated

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

Belgium, France, United States, Italy, Australia, Czech Republic, Netherlands, Ireland, Norway, Canada, Austria, Germany, Hungary, Ukraine
JOTEC GmbH
ICON plc

Recruiting

French Registry Conducted on E-vita OPEN NEO (NEO)

Vascular Aneurysm

France
Vasopharm GmbH
ICON plc

Completed

Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury (NOSTRA-III)

Traumatic Brain Injury

United Kingdom, Spain, France, Austria, Germany
Facet Biotech
PDL BioPharma, Inc.

Completed

Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease

Crohn's Disease

United States
PDL BioPharma, Inc.

Completed

Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

Melanoma | Metastases

United States
PDL BioPharma, Inc.

Terminated

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United States
BioNTech Cell & Gene Therapies GmbH

Recruiting

A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

Solid Tumor

Australia, Germany, Netherlands, Sweden
F2G Biotech GmbH
Hammersmith Medicines Research

Completed

Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim

Healthy

United Kingdom
F2G Biotech GmbH
PRA Health Sciences

Completed

Absorption, Metabolism and Excretion of 14C-olorofim in Man (hAME)

Invasive Fungal Infections

Netherlands
F2G Biotech GmbH
Simbec-Orion Group

Completed

Single Ascending Oral Dose Study of F901318

Invasive Aspergillosis

United Kingdom
Chemlmmune Therapeutics LLC
EURRUS Biotech GmbH

Completed

XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma

Eosinophilic Asthma | Bronchial Asthma

Russian Federation
F2G Biotech GmbH
Hammersmith Medicines Research

Completed

F901318 Multiple Ascending Dose Study

Invasive Aspergillosis

United Kingdom
F2G Biotech GmbH
Iqvia Pty Ltd

Recruiting

Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options (FORMULA-OLS)

Invasive Fungal Infections

United States, Netherlands, Israel, Spain, Korea, Republic of, Belgium, Australia, Germany, France, Brazil, Poland, Egypt, Russian Federation, Thailand, Turkey, United Kingdom, Vietnam
F2G Biotech GmbH
Hammersmith Medicines Research

Completed

Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe

Invasive Aspergillosis

United Kingdom
Sanofi
BioNTech RNA Pharmaceuticals GmbH

Terminated

A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Metastatic Neoplasm

France, Spain, United States, Belgium, Germany, Netherlands
Miltenyi Biomedicine GmbH
ICON plc

Recruiting

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU)

Diffuse Large B-cell Lymphoma

Spain, Germany, Netherlands, Belgium, France, Czechia, Austria, Lithuania, Poland, Sweden, Hungary, Italy
Steba Biotech S.A.
PrimeVigilance; ICON plc

Recruiting

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (UCM301)

Transitional Cell Cancer of Renal Pelvis and Ureter

United States, Israel, Spain, Italy, France, Germany, Austria
Miltenyi Biomedicine GmbH
ICON plc

Active, not recruiting

Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

B-cell Non Hodgkin Lymphoma

Germany

Clinical Trials Sponsored by PDC Biotech GmbH

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations